Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline

Jakafi-maker Incyte has effectively made Olumiant (baricitinib) — the tarnished JAK inhibitor dogged by safety concerns that barely crossed the FDA finish line with a smaller dose — Eli Lilly’s problem.